Table 1 Characteristics and results of studies evaluating oral eplerenone for the treatment of central serous chorioretinopathy
From: Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature
Study | Study design | N eyes | Disease duration | Visual acuity change | Subretinal fluid height change | Central macular thickness change | Follow-up | Side-effects |
|---|---|---|---|---|---|---|---|---|
Schwartz (2017) [38] | Prospective, randomized | 13 | Chronic | Improvement from 0.6 to 0.48 logMAR (p = 0.05) | Improvement from 143.3 to 101.7 μm (p = 0.021) | NA | 6 months | Increased CPK |
Pichi (2017) [37] | Prospective study | 20 | Chronic | Improvement from 0.2 to 0 logMAR (p = 0.03) | Improvement from 247 to 35 μm (p = 0.004) | NA | 2 months | Sedative effect and fatigue |
Rahimy (2017) [36] | Prospective, randomized controlled study | 15 | Chronic | Improvement from 0.394 ± 0.28 to 0.330 ± 0.27 logMAR (p = 0.04) | Improvement from 139.3 ± 58.7 to 51.8 ± 52.2 μm (p = 0.02) | Improvement from 366.2 ± 71.1 to 283.7 ± 65.4 μm (p = 0.02) | 9 weeks | Dizziness, diarrhea |
Gergely (2017) [35] | Prospective | 28 | Chronic | Improvement from 75.1 to 78.1 letters (p < 0.005) | Improvement from 207 to 120 μm (p < 0.005) | Improvement from 393 to 324 μm (p < 0.005) | 6 months | Dry mouth, dizziness, back pain, somnolence |
Sampo (2016) [34] | Retrospective series | 27 | Chronic | Improvement from 0.26 to 0.19 logMAR (p = 0.15) | Decrease of 93.04 μm (p = 0.00018) | Improvement from 371.6 to 294.3 μm (p = 0.038) | 3 months | Hyperkaliemia |
Cakir (2016) [33] | Retrospective series | 24 | Chronic | Improvement from 0.35 to 0.3 logMAR | Improvement from 117 to 65 μm | Improvement from 342 to 275 μm | 3 months | Myotonia, bowel irritation, hyperkaliemia |
Kapoor (2016) [32] | Retrospective series | 12 | Chronic | Improvement from 0.55 to 0.32 logMAR (p < 0.05) | ΝΑ | Improvement from 324.7 to 259.6 μm (p < 0.05) | 3 months | Fatigue, weight loss, gynecomastia |
Ghadiali (2016) [31] | Retrospective series | 3 | 2 Chronic, 1 Acute | Improvement from 0.67 to 0.75 decimal scale (p = 0.043) | ΝΑ | Improvement from 310.3 to 304.7 μm (p = 0.125) | 12 months | Hypertension |
Leisser (2015) [30] | Retrospective series | 11 | Chronic | Change in visual acuity from 0.48 to 0.71 logMAR | ΝΑ | Improvement from 455 to 389 μm | 3-38 weeks | Increased liver parameters, Increased potassium, Increase bilirubin level |
Chin (2015) [29] | Retrospective series | 15 | Chronic | Stability at 20/30 Snellen | NA | Improvement from 387.5 to 352.5 μm | NA | Fatigue, leg cramps, constipation, dehydration |
Salz (2015) [28] | Retrospective series | 14 | Chronic | Improvement from 0.41 to 0.28 logMAR (p = 0.01) | Improvement from 130 to 21 μm (p = 0.004) | NA | 3 months | None |
Singh (2015) [27] | Retrospective series | 17 | Chronic | Improvement from 0.42 to 0.29 logMAR (p = 0.024) | Improvement from 131.5 to 46.9 μm (p = 0.002) | Improvement from 339.5 to 270.3 μm (p = 0.029) | 6 months | None |
Breukink (2014) [26] | Retrospective series | 6 | Chronic | Improved in 2 patients | Decreased in 2 patients | NA | 5 weeks | None |
Bousquet (2013) [25] | Prospective, non-randomized uncontrolled open label study | 13 | Chronic | Improvement from 0.52 ± 0.24 to 0.27 ± 0.19 logMAR (p < 0.001) | Improvement from 175 ± 123 to 36 ± 55 μm (p < 0.01) | Improvement from 352 ± 139 to 189 ± 99 μm (p < 0.01) | 3 months | Fatigue, sedative effect |
Zhao (2012) [14] | Retrospective series | 3 | Chronic | Improvement from 0.43 to 0.8 decimal scale | Decreased in all eyes | NA | 5 months | None |